Focal Therapy Using HIFU for Localised Prostate Cancer

Inclusion Criteria: * Age≥ 50 years * Clinical stage T1c (normal digital rectal examination) or T2a (one palpable nodule on digital rectal examination) * PSA ≤10 ng / mL * Presence of cancer on biopsies (12 sampling biopsies plus 2-4 targeted biopsies on one side and limited to one or two contiguous areas of prostate: basic and middle or middle and apex). * Gleason score ≤ 7 (3+4) * Flowmetry \> 12 mL / sec for a voided volume of 125 mL * PVR \<100 mL * Patient with normal anal and rectal anatomy. * Patient with a condition corresponding to a classification of ASA 1 or 2. * Patient signing ICF and agreed for following monitoring Exclusion Criteria: * Patient with an ASA score 3. * Patient in clinical stage T1a, T1b, T2b, T2c or T3. * Patient with a tumor visible on MRI: Located at a distance less than 5 mm from the midline. Located less than 6 mm from the apex real * Metastatic lymph node or metastasis discovered by MRI and bone scan. * Patient previously treated for his prostate cancer by hormone therapy. * Patient with a distance between the rectal mucosa and prostate capsule over 8 mm thick * History of inflammatory bowel disease * Rectal fistula. * History of pelvic radiotherapy. * History of bladder cancer. * History of bladder neck sclerosis or urethral stenosis. * Patient with an implant located less than 1 cm from the treatment zone (stent, catheter). * Urogenital infection. * Latex allergy * Contraindication to MRI (pacemaker,metal prosthesis ...) * Patient participated in another clinical study within 30 days. * Illiterate patients * Legally incapable patients